Natixis’s vTv Therapeutics VTVT Stock Holding History

Natixis’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-563	Closed	-$42K	–	1196
2020 Q4	$42K	Buy	+563	New	+$43.2K	﹤0.01%	1029

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Natixis's VTVT Position: Q1 2021 in Review

Natixis sold out of vTv Therapeutics (VTVT) in Q1 2021, closing a stake of 563 shares — an estimated $42K sold.

Natixis first reported a position in VTVT in Q4 2020 and held it in 1 quarter. The position peaked at $42K in Q4 2020. 48 funds tracked by Wall St. Rank hold VTVT as of Q1 2021.

Natixis reported no remaining vTv Therapeutics position as of Q1 2021 after selling out during the quarter.
Natixis sold 563 vTv Therapeutics shares in Q1 2021, an estimated $42K.
Natixis first reported a position in vTv Therapeutics in Q4 2020 and held it in 1 quarter.
Natixis's vTv Therapeutics position peaked at $42K in Q4 2020.
48 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2021.

Based on Natixis's 13F filing for Q1 2021, filed 14 May 2021.